(S)-BI 2536 

(S)-BI 2536 (Compound 39g) is the enantiomer of BI 2536 (HY-50698). (S)-BI 2536 acts as an inhibitor of the BRD4 bromodomain and PLK1 kinase, with a K_i value of 54 nM against BRD4 and a K_i value of 0.42 nM against PLK1 kinase. (S)-BI 2536 exhibits anticancer activity against acute myeloid leukemia. (S)-BI 2536 can be used for the research of acute myeloid leukemia^[1].

(S)-BI 2536 inhibits purified BRD4 protein with a K_i of 54 nM, exhibiting comparable BRD4 binding affinity to the parent compound BI-2536^[1].
(S)-BI 2536 inhibits purified PLK1 protein with a K_i of 0.42 nM, showing 2-fold lower PLK1 binding affinity than the parent compound BI-2536^[1].
(S)-BI 2536 inhibits the viability of MV4-11 acute myeloid leukemia cells with a GI₅₀ of 0.019 μM, showing slightly reduced cell growth inhibitory activity compared to the parent compound BI-2536^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

521.65

C₂₈H₃₉N₇O₃

1241725-90-5

CC[C@@H]1N(C2CCCC2)C3=NC(NC4=C(C=C(C=C4)C(NC5CCN(CC5)C)=O)OC)=NC=C3N(C1=O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chen L, et al. BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. ACS Med Chem Lett. 2015;6(7):764-769. Published 2015 May 18.  [Content Brief]